Advanced Solutions for Sustained Delivery of Ocular Therapies
PharmaTech
JULY 4, 2025
While treatments for infection, inflammation, high eye pressure, and neovascularization have been shown to be effective, this method of delivery is considered “off-label,” as FDA has not approved products specifically for this use, except two intracameral implants (see below). PLoS ONE 2011 6, e24513. DOI:10.1089/jop.2022.0144
Let's personalize your content